Findings from National University of Singapore Yields New Findings on Cancer Gene Therapy (Customised Design of Antisense Oligonucleotides Targeting Egfr Driver Mutants for Personalised Treatment of Non-small Cell Lung Cancer).

Researchers at the National University of Singapore have developed a personalized treatment approach for non-small cell lung cancer (NSCLC) by using custom-designed antisense oligonucleotides (ASOs) to target specific mutations in the epidermal growth factor receptor (EGFR) gene. This strategy aims to overcome drug-resistant mutations and reduce toxicities associated with standard tyrosine kinase inhibitors (TKIs). By delivering EGFR-targeting ASOs via extracellular vesicles (EVs), the researchers have demonstrated promising results in inhibiting tumor growth in NSCLC models with EGFR mutations. This study highlights the potential of ASOs as an effective therapeutic platform for NSCLC treatment. [Extracted from the article]